AbCellera Biologics Inc.

ABCL

$11.36

+0.71%

2026-09-02 16:00:01 EDT+$0.08

Healthcare

Biotechnology

NASDAQ

Active Trading

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes ...

Price Action of ABCL

$11.36

+0.71%+$0.08

High—

Low—

52W High-9.7%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

AbCellera Biologics Inc. (NASDAQ: ABCL) is a Vancouver, Canada-based, clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. The company’s foundation is an advanced antibody discovery platform that uses AI and computational analysis to explore and interpret natural immune systems, allowing it to identify and develop antibodies with first-in-class ...AbCellera Biologics Inc. (NASDAQ: ABCL) is a Vancouver, Canada-based, clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. The company’s foundation is an advanced antibody discovery platform that uses AI and computational analysis to explore and interpret natural immune systems, allowing it to identify and develop antibodies with first-in-class or best-in-class potential. This platform is designed to support multiple therapeutic programs and modalities, and it serves as the engine behind both internally advanced drug candidates and externally partnered discovery efforts. From a business model perspective, AbCellera is known for combining proprietary technology with research collaboration and licensing relationships. The supplied information highlights a major research collaboration and license agreement with Eli Lilly and Company, illustrating how AbCellera can generate value through partner-funded discovery work as well as the downstream development potential of therapeutic antibody programs. In terms of products and services, the company provides antibody discovery and development capabilities rather than selling a conventional product line. Its “service-like” platform capabilities can be leveraged by biopharma partners seeking antibodies against specific targets, while AbCellera simultaneously develops its own differentiated antibody drug programs. As of late 2021, it had cultivated numerous discovery programs across completed, in-progress, and contract categories, reflecting an ongoing pipeline and engagement with multiple entities. Regarding costs and financial characteristics, the provided financial summary suggests a research-intensive, development-stage profile consistent with biotech operations: high research and development intensity relative to revenue (as reflected by R&D-to-revenue metrics in the dataset), negative profitability measures (e.g., negative margins and returns on assets/equity/earnings yield), and negative free cash flow metrics. This pattern typically indicates substantial ongoing investment in discovery and clinical development, with spending focused on building and advancing antibody programs until later commercialization stages. Key people include founder and CEO Carl Hansen, described as a founding CEO and scientific/entrepreneurial leader behind the company’s creation and technology approach. Overall, AbCellera’s strategic “wish” is to translate its antibody discovery advantage into a growing set of successful antibody therapeutics—whether through partnered programs or internally developed candidates—while maintaining a competitive edge in identification and characterization of drug-quality antibodies using AI-enabled discovery workflows.ExpandCollapse

Founded

2012

Employees

562

CEO

Carl Hansen

Full Name

AbCellera Biologics Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-17.49%

Market Cap

$3.47B

Current Ratio

12.77

WACC

9.88%

ROIC

-10.45%

Contact Information

https://www.abcellera.com

604 559 9005

150 W 4th Ave, Vancouver, BC V5Y 1G6

Key Metrics of ABCL

Snapshot

Latest / TTM · 6 periods

Market Cap

$3.47B

ROCE

-17.9%

EV / EBITDA

-22.14x

-1.2% YoY

FCF Yield

-5.1%

+12.0% YoY

Cash Conversion Cycle

426.6d

Current Ratio

12.77

Quick take

TTM —

Positive CCC

Financial Highlights of ABCL

Profitability trend

Latest / TTM · 6 periods

Gross Margin

75.0%

Net Margin

-248.8%

P/E Ratio

-21.43x

n/a

Debt / Equity

0.15

n/a

Current Ratio

12.77

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ABCL

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.15 · Revenue $5.32M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.18 · Revenue $6.32M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.66 · Revenue $25.16M · 4 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.19 · Revenue $7.83M · 1 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $-0.18 · Revenue $4.05M
View filing
May 11, 2026
Q1 FY2026 · Results reported
EPS $-0.14 · Revenue $8.31M
View filing
Feb 24, 2026
FY2025 · Annual results
EPS $-0.49 · Revenue $75.13M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.19 · Revenue $8.96M
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-0.12 · Revenue $17.08M
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.15 · Revenue $4.24M

Financial Statements of ABCL

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$75.1M	+160.6%	-51.3%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-146.4M	+10.1%	-28.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+61.6%	-38.4%	+2545.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-289.0%	+73.5%	-124.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-194.9%	+65.5%	-163.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-174.1M	+6.9%	+3.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-231.7%	+64.3%	-97.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	14.8%	+139.3%	+1.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	11.32x	+15.5%	-9.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$1.4B	-0.3%	+0.0%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.49 vs -0.58	+15.5%	-0.18 vs -0.15	-22.9%
Revenue Surprise	$75.1M vs $36.3M	+107.0%	$4.0M vs $5.3M	-23.9%

Insider Transactions of ABCL

Acquisitions (A)

Since Jun 11, 2026

Disposals (D)

Since Jun 11, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 24, 2026	Hayden Michael R	director	Common Shares	A	53,613	$10.64
Aug 18, 2026	Montalbano John S.	director	Common Shares	A	10,000	$11.03
Aug 14, 2026	Booth Andrew	officer: Chief Financial Officer	Common Shares	A	37,200	$10.32
Aug 12, 2026	Hayden Michael R	director	Common Shares	A	46,387	$10.37
Aug 11, 2026	Hayden Michael R	director	Common Shares	D	50,000	—

Earnings Call Transcript of ABCL

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good afternoon, and welcome to AbCellera's Q2 2026 Business Update Conference Call. My name is Jonathan, and I will facilitate the audio portion of today's interactive broadcast. At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. You may proceed. Tryn Stimart: Thank you. Hello, everyone. Thank you for joining us for AbCellera's Second Quarter 2026 Earnings Call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Dr. Carl Hansen, AbCellera's President and CEO; and Andrew Booth, AbCellera's Chief Financial Officer, are speaking on today's call. During this call, we may make statements about our strategic priorities and financial outlook based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described. Please review the Risk Factors section of our most recent Form 10-K and subsequent 10-Q filings with the SEC for a more detailed discussion of these risks. AbCellera assumes no obligation to update any forward-looking statements to reflect events or circumstances after today's date. Our presentation today, our earnings press release and our SEC filings are available on our Investor Relations website. The information we provide about our pipeline is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that this call is being recorded and will be available for replay on our Investor Relations website and that all dollars referred to during the call are U.S. dollars. After our prepared remarks, we will open the lines for questions and answers. Now I'll turn the call over to Carl. Carl L. Hansen: Thanks, Tyrn, and thank you, everyone, for joining us today. The most important data readout this year is the top line results for ABCL635 in the treatment of moderate to severe hot flashes associated with menopause. Last quarter, we shared our interim Phase I data that showed robust and sustained target engagement in healthy male volunteers and supported quickly advancing into a Phase II study in postmenopausal women experiencing moderate to severe hot flashes. Recruitment in this study accelerated through H1, and we completed enrollment and initial dosing of patients in June, well ahead of schedule. Based on this, we expect a top line data readout very soon. If the data is positive, we believe ABCL635 will be highly derisked. As noted in our last call, we've been preparing for next steps, which would include late-stage clinical development in moderate to severe VMS associated with menopause and clinical studies to evaluate ABCL635 in treating VMS associated with cancer treatment. Turning to our broader portfolio. ABCL-688 and ABCL386 continue to progress through IND-enabling …

Leadership Team of ABCL

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Carl Hansen	Chief Executive Officer, President & Chairperson	USD 931,152	—	1975	Active
Andrew Booth	Chief Financial Officer	USD 726,811	Male	1974	Active
Tryn T. Stimart	Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer	USD 709,275	Male	1970	Active
Veronique Lecault	Chief Technology Officer & Director	USD 681,646	—	1985	Active
Caitlin Webster CIPD	Director of Talent Development	—	—	—	Active
Marcie Thiessen	Senior Director of Finance & Accounting	—	—	—	Active
Andrew Knowles	Vice President of Operations	—	Male	—	Active
Martin Hogan	Senior Director of Strategic Finance & IR	—	Male	—	Active
Murray McCutcheon	Senior Vice President of Partnering	—	Male	—	Active
Tiffany Chiu	Vice President of Communications	—	Female	—	Active

Recent News of ABCL

Benzinga8/25/2026Neutral

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.

Seeking Alpha8/16/2026Neutral

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Business Wire8/13/2026Neutral

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.

Benzinga8/12/2026Neutral

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.

Business Wire8/11/2026Neutral

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.

Historical Employee Count of ABCL

Current

562

Change

-5.70%

Minimum

386

Maximum

596

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	562	10-K	Feb 24, 2026	View
Dec 31, 2024	596	10-K	Feb 27, 2025	View
Dec 31, 2023	586	10-K	Feb 20, 2024	View
Dec 31, 2022	495	10-K	Feb 21, 2023	View
Dec 31, 2021	386	10-K	Feb 25, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

AbCellera Biologics Inc.